川崎病静脉注射免疫球蛋白后六个月接种减毒活疫苗的效力
本研究为单臂前瞻性干预试验,纳入32例川崎病患儿,在静脉注射免疫球蛋白(IVIG)治疗后6个月首次接种麻疹、风疹、水痘、腮腺炎减毒活疫苗,9个月时检测抗体,阴性者12个月时加强接种。初种后麻疹、风疹、腮腺炎、水痘血清转化率分别为88%、78%、6%、16%;加强后分别为100%、100%、97%、77%。结论:单剂IVIG后6个月接种血清转化率低,但12个月加强接种可实现血清转化。
要点
- 川崎病IVIG后6个月接种麻疹、风疹、水痘、腮腺炎减毒活疫苗的血清转化率低。
- 12个月加强接种后麻疹、风疹血清转化率达100%,腮腺炎97%,水痘77%。
- 初种后腮腺炎和水痘血清转化率尤其低,需加强接种。
核心结论
- 川崎病患儿在单剂IVIG治疗后6个月接种减毒活疫苗的血清转化率低,但12个月加强接种可实现血清转化。
研究设计与样本
- 单臂前瞻性干预研究,纳入32例年龄≥6个月、无麻疹、风疹、水痘或腮腺炎病史及疫苗接种史的川崎病患儿,在IVIG治疗后6个月首次接种上述疫苗,9个月检测病毒特异性IgG,阴性者12个月加强接种。
主要发现
- IVIG治疗后6个月时,9%的受试者麻疹抗体阳性,6%水痘抗体阳性,腮腺炎和风疹抗体均为阴性。
- 初种后麻疹、腮腺炎、风疹、水痘的血清转化率分别为88%、6%、78%、16%。
- 加强接种后麻疹和风疹血清转化率为100%,腮腺炎97%,水痘77%。
关键数值与推荐
- 初种后麻疹血清转化率88%,风疹78%,腮腺炎6%,水痘16%。
- 加强接种后麻疹和风疹血清转化率100%,腮腺炎97%,水痘77%。
临床怎么用
- 川崎病IVIG治疗后6个月接种减毒活疫苗时,应计划在12个月时加强接种以提高血清转化率。
局限性
- 本研究为单臂设计,样本量32例,未设对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Due to the presence of maternal passive antibodies, the measles vaccine is ineffective if administered before age 12-15 months. The optimal timing for administering a live attenuated vaccine (LAV) after intravenous immunoglobulin therapy (IVIG) for Kawasaki disease (KD) has not been fully investigated. The recommended interval between vaccination and IVIG therapy for KD differs by country. The present study aimed to evaluate efficacy of LAV six months after IVIG therapy for KD in Japan. METHODS: The present, single-arm, prospective, interventional study included patients aged 6 months or older with no medical history of measles, rubella, varicella or mumps or vaccinations against these diseases. The subjects received these vaccinations for the first time at six months after IVIG therapy. Virus-specific IgG levels for each virus measured by EIA was examined at nine months after IVIG therapy. If the results were negative, the subjects received a booster vaccination at 12 months after IVIG therapy. The primary outcome was the prevalence of positivity for antibodies after the initial and booster vaccinations. RESULTS: The present study enrolled 32 subjects, 31% of whom were female, with an average age of 10.8 (standard deviation 2.8) months at IVIG therapy. At six months after IVIG therapy, 9% and 6% of the subjects were seropositive for measles and varicella titers, respectively, but were seronegative for the mumps and rubella titers. The seroconversion rate for measles, mumps, rubella, and varicella after the initial vaccination was 88%, 6%, 78%, and 16%, respectively. The seroconversion rate after a booster vaccination was 100% for measles and rubella, 97% for mumps, and 77% for varicella. CONCLUSIONS: The seroconversion rate was low for LAV at six months after a single dose of IVIG for KD, but seroconversion was achievable with a booster vaccination at 12 months. CLINICAL TRIAL REGISTRATION: UMIN-CTR, UMIN000007174, https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000008452.
引用
- Morikawa Y, Sakakibara H, Kimiya T, et al. Live attenuated vaccine efficacy six months after intravenous immunoglobulin therapy for Kawasaki disease. Vaccine. 2021. PMID: 34452773. doi:10.1016/j.vaccine.2021.07.097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。